Sanxin Medtec CFO Steps Down
Jiangxi Sanxin Medtec's (SHE:300453) Chief Financial Officer Zou Beiting resigned for personal reasons, according to a Monday filing with the Shenzhen Stock Exchange. The medical device maker has not
Sanxin Medical (300453.SZ): The repurchase was completed with a cumulative cost of 43.4529 million yuan to repurchase 8.295,700 shares
Gelonghui May 31,丨Sanxin Medical (300453.SZ) announced that the company's actual repurchase period is from February 2, 2024 to May 31, 2024. As of the disclosure date of this announcement, the company has repurchased 8,295,650 shares of the company's shares through centralized bidding transactions through a special securities account. The repurchased shares account for 1.60% of the company's total share capital, the highest transaction price is 5.60 yuan/share, and the lowest transaction price is 4.90 yuan/share. The repurchase capital has been 43.4529 million yuan (excluding transaction fees). The company's current share repurchase plan has all been implemented.
Sanxin Medical (300453.SZ): Financial Director Zou Beiting Resigns
Zhitong Finance App News, Sanxin Healthcare (300453.SZ) issued an announcement. The board of directors of the company recently received a written resignation report from financial director Zou Beiting. Zou Beiting applied to resign as the company's financial director due to personal reasons. His original term of office was from April 13, 2023 to April 12, 2026. After his resignation, Zou Beiting will no longer hold any position in the company or its subsidiaries.
Sanxin Medical (300453.SZ) plans to pay 1.5 yuan for 10 shares to be deducted from interest on April 25
Sanxin Medical (300453.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...
Sanxin Medical (300453.SZ): Net profit of 53.618,700 yuan in the first quarter increased 19.72% year-on-year
Gelonghui, April 16, 丨 Sanxin Medical (300453.SZ) released its report for the first quarter of 2024, with operating income of 331 million yuan, up 21.34% year on year; net profit attributable to shareholders of listed companies was 53.618,700 yuan, up 19.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 467.935 million yuan, up 28.61% year on year; basic earnings per share were 0.1032 yuan.
Jiangxi Shengdankang, a wholly-owned subsidiary of Sanxin Medical (300453.SZ), received a medical device production license
Sanxin Medical (300453.SZ) announced that Jiangxi Shengdankang Medical Technology Co., Ltd., a wholly-owned subsidiary of the company (abbreviation...
Sanxin Medical (300453.SZ): The products of the holding subsidiary passed the innovative medical device review
Sanxin Medical (300453.SZ) announced that recently, Jiangxi Colevide Biotechnology Co., Ltd., a holding subsidiary of the company...
We Think You Should Be Aware Of Some Concerning Factors In Jiangxi Sanxin MedtecLtd's (SZSE:300453) Earnings
Jiangxi Sanxin Medtec Co.,Ltd. (SZSE:300453) just released a solid earnings report, and the stock displayed some strength. While the profit numbers were good, our analysis has found some concerning f
The subsidiary of Sanxin Medical (300453.SZ) Holdings obtained a medical device production license
According to the Zhitong Finance App, Sanxin Medical (300453.SZ) announced that the company's holding subsidiary Jiangxi Colectin Biotechnology Co., Ltd. (“colevipid” for short) has obtained a “Medical Device Production License” issued by the Jiangxi Drug Administration. The acquisition of the “Medical Device Production License” by Colectin is based on actual production and operation needs. It helps the company promote the production and operation of medical devices related to vascular access and peripheral vascular intervention, improves the company's industrial layout, further enhances the company's market competitiveness, and will have a positive impact on the company's future production and operation.
Sanxin Medical (300453.SZ): Net profit for 2023 increased 11.92% to 207 million yuan, and plans to pay 10 to 1.5 yuan
Gelonghui March 22丨Sanxin Healthcare (300453.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,300 million yuan, a year-on-year decrease of 2.69%; net profit attributable to shareholders of listed companies was 207 million yuan, up 11.92% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 181 million yuan, up 8.56% year on year; basic earnings per share was 0.3987 yuan; it plans to distribute a cash dividend of 1.5 yuan (tax included) to all shareholders for every 10 shares.
Sanxin Medical (300453.SZ): 1.60% of shares have been repurchased cumulatively
Gelonghui, March 1, 丨 Sanxin Medical (300453.SZ) announced that as of February 29, 2024, the company had repurchased 8,295,650 shares of the company's shares through a dedicated securities account. The repurchased shares accounted for 1.60% of the company's total share capital. The highest transaction price was 5.60 yuan/share, and the minimum transaction price was 4.90 yuan/share. The repurchase capital had been 43,452,867.60 yuan (not including transaction fees).
Sanxin Medical (300453.SZ): Sichuan Weilisheng passed the high-tech enterprise certification for the first time
Gelonghui, Feb. 19: Sanxin Medical (300453.SZ) announced that its wholly-owned subsidiary, Sichuan Weilisheng Medical Technology Co., Ltd. (“Sichuan Weilisheng”), recently received the “High-tech Enterprise Certificate” jointly issued by the Sichuan Provincial Department of Science and Technology, the Sichuan Provincial Department of Finance, and the Sichuan Taxation Bureau of the State Administration of Taxation, and passed the certification of a high-tech enterprise for the first time.
Sanxin Medtec's Unit Registers Colon Cleansing Device; Shares Up 3%
Jiangxi Sanxin Medtec's (SHE:300453) subsidiary, Jiangxi Shengdankang Medical Technology, obtained a medical device registration certificate for its intestinal hydrotherapy machine. The device is used
Sanxin Medical (300453.SZ): Intestinal hydrotherapy machine obtained medical device registration certificate
Zhitong Finance App News, Sanxin Medical (300453.SZ) announced that Jiangxi Shengdankang Medical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the “Medical Device Registration Certificate” issued by the Jiangxi Drug Administration. The product name is an intestinal hydrotherapy machine, which is mainly used for colon cleansing.
Sanxin Medical (300453.SZ): 1.58% of shares have been repurchased cumulatively
Gelonghui, Feb. 7, 丨 Sanxin Medical (300453.SZ) announced that as of February 7, 2024, the company had repurchased 8,195,650 shares of the company's shares through a dedicated securities account, accounting for 1.58% of the company's current total share capital (519,596,545 shares). The highest transaction price of the repurchase was 5.60 yuan/share, and the minimum transaction price was RMB 4.90 yuan/share, and the total transaction amount was RMB 42.9569 million (excluding transaction fees).
Sanxin Medical (300453.SZ) obtained vascular sheath medical device registration certificate
Sanxin Medical (300453.SZ) issued an announcement that Jiangxi Colectin Biotechnology Co., Ltd., a wholly-owned subsidiary of the company,...
Jiangxi Sanxin Medtec Co.,Ltd. (SZSE:300453) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
The Jiangxi Sanxin Medtec Co.,Ltd. (SZSE:300453) share price has fared very poorly over the last month, falling by a substantial 29%. Instead of being rewarded, shareholders who have already held t
Sanxin Medical (300453.SZ): Plans to spend 30 million yuan to 60 million yuan to buy back the company's shares
Gelonghui, Feb. 2: Sanxin Medical (300453.SZ) announced that it plans to repurchase RMB common stock (A shares) shares issued by the company to implement employee stock ownership plans or equity incentives. The total amount of capital to be used for the repurchase is not less than RMB 30 million (inclusive) and not more than RMB 60 million (inclusive), and the price of the shares to be repurchased is no more than RMB 10.77 per share (inclusive). Based on the upper limit of the proposed repurchase price and the repurchase amount range, the number of shares to be repurchased is not less than 2.785,600 shares, accounting for 0.54% of the company's total share capital and no higher than 5571,000 shares, accounting for the company
Jiangxi Sanxin Medtec Co.,Ltd.'s (SZSE:300453) Last Week's 13% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake
Key Insights The considerable ownership by individual investors in Jiangxi Sanxin MedtecLtd indicates that they collectively have a greater say in management and business strategy The top 25 shareho
Sanxin Medical (300453.SZ) obtained a medical device registration certificate for single-use sterile anti-acupuncture needles
Sanxin Medical (300453.SZ) announced that the company recently obtained “Medical Devices...” issued by the State Drug Administration
No Data